Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Maximilian Bockhorn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7027-6606; OpenAlex author ID A5031715528, A5083444146. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 1 paper · 2014: 8 papers · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 31

  1. Preoperative Anemia as a Prognostic Risk Factor for Inferior Oncological Survival Following Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002448↗
  2. It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2025.1495907↗
  3. Association Between Physical Activity and Pancreatic Cancer Risk and Mortality: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers16213594↗
  4. Nanoparticle-based immunotherapy of pancreatic cancer. Co-author DOI 10.3389/fmolb.2022.948898↗
  5. Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Co-author DOI 10.1093/glycob/cwab088↗
  6. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
  7. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Last author DOI 10.1016/j.ejso.2018.12.012↗
  8. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-18-0120↗
  9. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Co-author DOI 10.1080/15384047.2017.1281499↗
  10. Pancreatic cancer and liver metastases: state of the art. Last author DOI 10.1007/s13304-016-0407-7↗
  11. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… Last author DOI 10.1016/j.surg.2016.02.019↗
  12. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv387↗
  13. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. Co-author DOI 10.1002/jso.23826↗
  14. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? Last author DOI 10.1007/s00268-014-2808-4↗
  15. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0386-1↗
  16. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  17. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗
  18. Pancreatic cancer. Last author DOI 10.1111/bph.12401↗
  19. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0716↗
  20. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-13-0467↗
  21. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinom… Co-author DOI 10.1186/1471-2407-14-411↗
  22. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0113023↗
  23. Serum EpCAM expression in pancreatic cancer. Last author PMID 25202052↗
  24. Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp--/rag2-- mice. Co-author DOI 10.1136/gutjnl-2011-300629↗
  25. Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival. Last author DOI 10.1002/ijc.26439↗
  26. ALCAM (CD166) expression and serum levels in pancreatic cancer. Last author DOI 10.1371/journal.pone.0039018↗
  27. Surgery for advanced and metastatic pancreatic cancer--current state and trends. First author PMID 22593478↗
  28. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. Last author DOI 10.1002/jso.21957↗
  29. Multivisceral resections in pancreatic cancer: identification of risk factors. Last author DOI 10.1007/s00268-011-1263-8↗
  30. Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? First author DOI 10.1007/s11605-011-1469-y↗
  31. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Last author DOI 10.1158/0008-5472.can-11-0036↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jakob Robert Izbicki · 24 shared papers, 2011–2021 · strength 1.09
  2. N. Helge Meyer · 4 shared papers, 2022–2025 · strength 0.93
  3. Maarten W. Nijkamp · 3 shared papers, 2024–2025 · strength 0.75
  4. Florian Gebauer · 14 shared papers, 2011–2018 · strength 0.63
  5. Michael Tachezy · 14 shared papers, 2011–2018 · strength 0.63
  6. Gaetan Aime Noubissi Nzeteu · 2 shared papers, 2022–2025 · strength 0.47
  7. Mylena D. Bos · 2 shared papers, 2024–2025 · strength 0.47
  8. Cenap Güngör · 8 shared papers, 2011–2021 · strength 0.45
  9. Gerrit Wolters‐Eisfeld · 6 shared papers, 2014–2021 · strength 0.37
  10. Yogesh Kumar Vashist · 9 shared papers, 2011–2015 · strength 0.33
  11. Bianca T. Hofmann · 5 shared papers, 2014–2021 · strength 0.33
  12. Christin Knickmeier · 1 shared paper, 2025 · strength 0.28
  13. Joost M. Klaase · 1 shared paper, 2025 · strength 0.24
  14. Allard G Wijma · 1 shared paper, 2025 · strength 0.24
  15. Joost M. Klaase · 1 shared paper, 2024 · strength 0.23
  16. Faik Güntac Uzunoglu · 4 shared papers, 2014–2020 · strength 0.23
  17. Kai A. Bachmann · 3 shared papers, 2014–2021 · strength 0.21
  18. Udo Schumacher · 4 shared papers, 2013–2020 · strength 0.20
  19. Mustapha Adham · 4 shared papers, 2014–2019 · strength 0.19
  20. Alexander T. El Gammal · 3 shared papers, 2015–2020 · strength 0.17
  21. Katharina E. Effenberger · 4 shared papers, 2011–2018 · strength 0.16
  22. Emre F. Yekebas · 4 shared papers, 2011–2015 · strength 0.15
  23. Claudio Bassi · 3 shared papers, 2014–2019 · strength 0.14
  24. Matthias Reeh · 3 shared papers, 2011–2019 · strength 0.13
  25. Giuseppe Malleo · 2 shared papers, 2016–2019 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.